PPD Receives Award Recognizing Employee Talent Development
September 01 2021 - 9:00AM
Business Wire
PPD, Inc. (Nasdaq: PPD) has been recognized as one of the best
in the world for its successful employee learning and development
programs by the Association for Talent Development (ATD), a global
organization that empowers and supports professionals to develop
talent in the workplace.
PPD is a recipient of the 2021 ATD BEST Awards, which recognize
enterprise-wide success as a result of employee talent development.
PPD is committed to attracting, developing and retaining top talent
in the industry, and this year, PPD ranked second out of 71
companies in the 2021 BEST Awards Winners' Circle, which includes
small and large private, public and not-for-profit organizations
from around the world.
“PPD goes to great lengths to invest in and develop our
colleagues through our robust training programs, and this award
reflects our successful efforts in providing effective professional
development for our global workforce,” said Jay Dixon, senior vice
president of quality and enterprise learning at PPD. “Our learning
culture increases employee engagement and retention and allows us
to better serve our customers and their drug-development
initiatives, needs and goals.”
Employee learning and development at PPD includes leadership and
high-potential development, key talent programs, technical skills,
job-specific and soft skills training, all of which are integrated
and aligned with business goals and objectives. TD Magazine, ATD’s
flagship magazine, recently profiled PPD and showcased its
award-winning talent development efforts through the virtual
learning platform.
The ATD BEST Awards celebrate and honor those companies that use
talent development as a strategic business tool to deliver results.
Judges for the 2021 ATD BEST Awards received and reviewed hundreds
of entries this year. As an award recipient, PPD successfully
demonstrated that it has excelled in various aspects of talent
development, including creating solutions to business issues,
providing learning opportunities for employees at all levels within
the company and measuring the effectiveness of its learning
programs.
ATD’s members and customers come from more than 120 counties,
and they are professionals who help others achieve their full
potential by improving their knowledge, skills and abilities in the
workplace.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our customers and partners include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With more than 28,000 professionals
worldwide, PPD has conducted clinical trials in more than 100
countries to help customers deliver life-changing therapies to
improve health. We apply innovative technologies, therapeutic
expertise and a firm commitment to quality to bend the cost and
time curve of drug development and optimize value. For more
information, visit www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the proposed merger of
PPD by Thermo Fisher Scientific Inc.; and other factors disclosed
under the “Risk Factors” section in our periodic reports filed with
the Securities and Exchange Commission (SEC), including our latest
Annual Report on Form 10-K and Quarterly Report on form 10-Q, which
are available on our website at https://investors.ppd.com or the
SEC’s website at www.sec.gov. We assume no obligation and disclaim
any duty to revise or update any forward-looking statements, or
make any new forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210901005617/en/
PPD Contacts Media: Nadine Maeser +1 919 456 4425
media@ppd.com
Investors: Tracy Krumme +1 910 558 4186 investors@ppd.com
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Jul 2023 to Jul 2024